CFM Wealth Partners LLC Sells 12,452 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Apr 1st, 2023

CFM Wealth Partners LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 83.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,455 shares of the company’s stock after selling 12,452 shares during the quarter. CFM Wealth Partners LLC’s holdings in Johnson & Johnson were worth $434,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in JNJ. Veracity Capital LLC grew its stake in Johnson & Johnson by 1.2% in the fourth quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after purchasing an additional 59 shares in the last quarter. Sandy Cove Advisors LLC increased its holdings in shares of Johnson & Johnson by 1.6% in the third quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock valued at $605,000 after buying an additional 60 shares in the last quarter. Paces Ferry Wealth Advisors LLC increased its holdings in shares of Johnson & Johnson by 0.7% in the third quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock valued at $1,425,000 after buying an additional 62 shares in the last quarter. Mason & Associates Inc raised its stake in Johnson & Johnson by 4.9% during the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock valued at $215,000 after purchasing an additional 62 shares during the period. Finally, Magnolia Capital Advisors LLC raised its stake in Johnson & Johnson by 0.7% during the 3rd quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company’s stock valued at $1,451,000 after purchasing an additional 62 shares during the period. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.35% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. SVB Leerink decreased their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Atlantic Securities raised their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a report on Wednesday, January 25th. StockNews.com assumed coverage on shares of Johnson & Johnson in a research note on Thursday, March 16th. They set a “strong-buy” rating on the stock. UBS Group started coverage on shares of Johnson & Johnson in a research report on Tuesday. They set a “neutral” rating and a $164.00 price target on the stock. Finally, Guggenheim assumed coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective on the stock. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $173.67.

Johnson & Johnson Stock Up 1.0 %

Shares of NYSE JNJ opened at $155.00 on Friday. The firm has a market cap of $403.66 billion, a PE ratio of 23.00, a P/E/G ratio of 2.64 and a beta of 0.54. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $186.69. The company’s fifty day simple moving average is $158.02 and its 200 day simple moving average is $167.12. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.13. The firm had revenue of $23.71 billion for the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business’s revenue was down 4.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.13 earnings per share. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were issued a dividend of $1.13 per share. The ex-dividend date was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.92%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 67.06%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.